www.cancervaccinesevent.com Register online or fax your registration to +44 (0) 870 9090 712 or call +44 (0) 870 9090 711

ACADEMIC & GROUP DISCOUNTS AVAILABLE

PLUS ONE INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPTuesday 26th September 2017, Copthorne Tara Hotel, London, UK

@SMIPHARM#cancervac17

Biomarkers of Immune Response 12.30 – 16.00

Workshop Leaders: Rose-Ann Padua, Research Director, INSERM | Antoine Toubert, Head, Alloimmunity, Autoimmunity, Transplantation, INSERM Eric Tartour, Head, Laboratory of Clinical Immunology, Hopital Europeen George Pompidou | Sharam Kordasti, Senior Lecturer, Kings College London

Zwi Berneman, Professor of Haematology, University of Antwerp

SMi proudly present the 6th annual conference…

Cancer Vaccines Overcoming hurdles to cancer immune response: Cell therapies, vaccine development and combination therapies

Copthorne Tara Hotel, London, UK

CONFERENCE: 27TH - 28TH

WORKSHOP: 26TH

SEPT 2017

Highlights in 2017: • Exploring the potential of the personalisation

of cancer therapies • Maximising therapeutic potential by combining

therapies with immune checkpoint inhibitors • In-depth case study examples of peptide, DNA,

neoantigen and MHC based therapy development • Assessing the use of pre-clinical data

CHAIRS:• Jonathan Zalevsky, Senior Vice President Biology

and Pre-Clinical Development, Nektar Therapeutics• Alfredo Nicosia, CEO, Nouscom srl/ Reithera srl

FEATURED SPEAKERS: • Kandeepan Ganeshalingam, Executive Director,

Therapeutic Area Head Oncology, MSD • Fatema Legrand, Senior Clinical Scientist, Genentech • David Giljohann, CEO, Exicure • Jonathan Zalevsky, Senior Vice President Biology and

Pre-Clinical Development, Nektar Therapeutics • Agnete Fredriksen, Chief Scientifi c Offi cer, Vaccibody • Mads Hald Andersen, Professor and Vice-Director, Centre

for Cancer Immune Therapy, Copenhagen University Hospital; Founder, IO Biotech

• Rose-Ann Padua, Research Director, INSERM • Zahra Jawad, Group Leader in Discovery Technology,

Agenus

Sponsored by

Cancer Vaccines Day One | Wednesday 27th September 2017

08.30 Registration & Coffee

09.00 Chairman’s Opening Remarks Jonathan Zalevsky, Senior Vice President Biology and Pre-Clinical

Development, Nektar Therapeutics

AUTOLOGOUS TUMOUR CELL IMMUNOTHERAPY

OPENING ADDRESS 09.10 Generation of fully personalised cancer vaccines with a potent,

cost-effective and robust technology • How to increase potency of neoantigen-based cancer

vaccines without increasing manufacturing complexity • Do we need to optimise neoepitope selection for each

therapeutic modality? • What is the optimal number of neoepitopes to include in a

single cancer vaccine? • Key criteria for designing a successful basket trial in multiple

indications with individualised cancer vaccines Agnete Fredriksen, Chief Scientifi c Offi cer, Vaccibody

09.50 Combined adjuvants for synergistic activation of cellular immunity (CASAC)

• Induction of therapeutically effective cellular immunity against cancer associated antigens, for immune therapy of cancer, remains a major challenge

• Given the age associated prevalence of cancer, therapeutic vaccination needs to be effective in conditions of immune senescence

• Therapeutic outcome in response to vaccination will also be dependent on the effective blockade of tumour induced immune suppression, tumour microenvironment, and adequate access of the effector cells to the target cells and tissues

• The development of a platform for screening based identifi cation of combinations of immune regulators, enabling the induction of very effective stimulation of antigen specifi c cellular immunity will be described.

• The path to the clinical evaluation of a number of strategies for the vaccination induced cellular immunity will be discussed

Farzin Farzaneh, Professor of Molecular Medicine, Kings College London

10.30 Morning Coffee

11.00 DCVax®: Novel personalised immune therapies for solid tumors • DCVax® is a fully personalised precision medicine, tailored to

the individual patient and their tumor. • DCVax® is designed to mobilise many active agents of the

immune system to hit many targets on the cancer, unlike conventional cancer drugs and some other immune therapies, which generally use a single active agent to hit a single target on the cancer.

• A full course of DCVax® doses can be manufactured in a single batch within about a week, and can be stored frozen until needed (including for years)

Linda Powers, CEO, Northwest Biotherapeutics

COMBINATION THERAPIES

11.40 Therapeutic potential of cancer vaccines and immune checkpoint inhibitors

• Rise of immune checkpoint inhibitors in the therapeutic development for cancer

• Priming of patients with cancer vaccines for the treatments with immune checkpoint inhibitors

• Synergistic function of the combination of cancer vaccines and immune checkpoint inhibitors, like the aPD1 Pembrolizumab in the induction of more effective antitumor immune responses

Kandeepan Ganeshalingam, Executive Director, Therapeutic Area Head Oncology, MSD

12.20 Networking Lunch

13.30 Activation of the immune system in combination with checkpoint inhibitors

• Spherical Nucleic Acid (SNA™) are nanoscale, spherical arrangements of densely packed and radially oriented nucleic acids

• Localisation to endosome permits large numbers of SNA’s to be delivered with low toxicity

• By activating innate immune cells, SNA’s enhance the function and secretion of cytokines

• AST-008 is a TLR9 agonist oligonucleotide in SNA format which demonstrates greater delivery to primary cells and more potent TLR9 activation in cell-based assays

• AST-008 has been evaluated in numerous solid and liquid tumour models, including breast, colon, bladder, melanoma and lymphoma

• Combining AST-008 with a checkpoint inhibitor (PD-1) results in a profound impact on tumour growth and survival

• An update on clinical progress will be provided David Giljohann, CEO, Exicure

14.10 Cancer immunotherapy combination development strategies • The cancer-immune set point and rational combination design • The MORPHEUS platform: an applied trial concept for rapid

development of combinations • Personalised cancer vaccines Speaker to be confi rmed

14.50 Afternoon Tea

15.20 Cell wars: the immune system fi ghts back • A DNA vaccine in combination with an immunomodulatory

all-trans retinoic acid (ATRA) eliciting specifi c immune responses in myeloid malignancies with a reduction of tumour burden and antibody response

• Real time imaging reveals effector cells inducing cell death of target cells

• Depletion experiments show that the protective effects are immune mediated

• Nf-kB signalling molecules upregulated Rose-Ann Padua, Research Director, INSERM

16.00 Panel discussion: Will cancer vaccines ever exist? • How do we defi ne ‘successful treatment’? - Patient survival? - Response rate to treatment? • Single vs. combination therapies • What are the implications of a vaccine no longer being a

replacement technology but a companion technology? Moderated by: Kandeepan Ganeshalingham, Executive Director, Therapeutic

Area Head Oncology, MSD Farzin Farzaneh, Professor of Molecular Medicine,

Kings College London Agnete Fredriksen, Chief Scientifi c Offi cer, Vaccibody

16.40 Chairman’s Closing Remarks and Close of Day One

Register online at www.cancervaccinesevent.com

Supported byOffi cial PublicationsSponsored by

NW Bio is developing DCVax® dendritic cell-based therapeutic vaccines. The Company’s DCVax®-L for resectable solid tumors is in a 331-patient Phase III trial for newly diagnosed GBM and Phase II trials in combination with checkpoint inhibitor drugs are planned. The Company’s DCVax®-Direct for inoperable solid tumors has completed a 40-patient Phase I trial for diverse cancers; various Phase II trials are planned. www.nwbio.com

Cancer Vaccines Day Two | Thursday 28th September 2017

08.30 Registration & Coffee

09.00 Chairman’s Opening Remarks Alfredo Nicosia, CEO, Nouscom srl/ Reithera srl

PRECLINICAL DEVELOPMENT OF VACCINES

09.10 Enhanced cancer vaccine effectiveness with NKTR-214, a CD122-biased cytokine

• NKTR-214 biases signalling through the IL-2 receptor pathway to generate profound effector T-cell responses while reducing regulatory T-cell activity in tumours

• Combination dosing of NKTR-214 dramatically enhances activity of several tumour vaccine modalities in mouse models

• The unique profi le of T-cell activity generated by NKTR-214 may enable the next generation of tumour vaccines

Jonathan Zalevsky, Senior Vice President Biology and Pre-Clinical Development, Nektar Therapeutics

09.50 Vaccines with phosphopeptides • Phosphopeptides as an alternative to peptides for vaccinations • New data showing the immunogenicity profi le of

phosphopeptides • Pre-clinical models of anti-tumour effi cacy Zahra Jawad, Group Leader in Discovery Technology, Agenus

10.30 Morning Coffee

NEW APPROACHES TO CANCER VACCINES

11.00 Nouscom neo-antigen based viral vectored vaccine and a novel potent immunomodulator show synergistic activity in mouse cancer model

• Great Ape Adenovectors (GAd) are clinically validated genetic vaccine carriers with excellent safety and ability to induce potent CD8 T cell responses with effector memory phenotype

• GAd vectors encoding large numbers of cancer-specifi c neo-antigens induced potent and broad T cell responses in mice

• Combination of GAd vectors with check-point inhibitors improved immunogenicity and effi cacy in tumor bearing mice

• Combination of GAd vectors and a novel potent immunomodulator led to almost 100% cure in mice lending support to a novel approach for combination therapy in the immune oncology fi eld

Alfredo Nicosia, CEO, Nouscom srl/ Reithera srl

11.40 In vitro validation of potential neo-epitopes by MHC based reagents

• Affi nity vs. Stability based peptide MHC assays, implications on current in silico tools

• What does a neo-epitope look like from the MHC perspective? • High throughput MHC tetramer production to support

personalised cancer vaccination trials Sune Justesen, Chief Scientifi c Offi cer, ImmuniTrack

12.20 Networking Lunch

13.30 Targeting the tumor microenvironment with vaccine-activated anti-regulatory T cells

• Describe the discovery of self-reactive, pro-infl ammatory T cells-termed anti-regulatory T cells (anti-Tregs) - effector T cells that specifi cally target immune-suppressive cells (including cancer cells)

• Providing examples of antigen-specifi c anti-Tregs • Discussing their possible roles in immune homeostasis • Current clinical vaccination trials and potential future clinical

applications Mads Hald Andersen, Professor and Vice-Director, Centre for

Cancer Immune Therapy, Copenhagen University Hospital; Founder, IO Biotech

14.10 Individualised mRNA cancer immunotherapy • Development of nanoparticle formulation for systemic

RNA delivery • Liposome formulated RNAs (RNA-Lipoplex) • Personalised cancer vaccine (IVAC® platform) Ludwig Heesen, Project Manager, BioNTech AG

14.50 Afternoon Tea

ENHANCING CANCER VACCINE EFFICACY

15.20 Immune modulation as an essential tool for cancer vaccines • Cancer vaccines require an optimal adjuvant • The ‘work’ better with correct immune modulation • Immune modulation can be achieved with IMiDs

(Thalidomide analogues) or low dose chemotherapy • Some agents, such as IMM-101 were developed as cancer

vaccines but are actually very powerful immune modulators Angus Dalgleish, Professor of Oncology,

St George’s University of London

16.00 In vitro assays to accelerate cancer therapy development • In vitro assays using primary human cells are a useful tool to

screen the functional properties of lead molecules/therapies and to document the mechanism of action

• Development of potency assays • Functional screening of immune checkpoint inhibitors Sofi e Pattijn, Chief Technology Offi cer, ImmunXperts

16.40 Effect of adjuvant/delivery system(s) on vaccine effi cacy, two examples of PAP/HAGE* vaccines

• How a single amino-acid can change the immunogenicity of your vaccine

• How different adjuvants affect differently the immunogenicity of vaccine

• How different delivery systems also affect differently the immunogenicity of vaccine

Stephanie McArdle, Senior Research Scientist in Immunology, The John van Geest Research Centre, Nottingham Trent University (*sequences patented)

17.20 Chairman’s Closing Remarks and Close of Day Two

Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711

MARKETING OPPORTUNITIES

Want to know how you can get involved? Interested in promoting your services to

this market? Contact Kyra Williams,

SMi Marketing on +44 (0) 20 7827 6012 or email:

kwilliams@smi-online.co.uk

Supported by

Biomarkers of immune response

Leader: Rose-Ann Padua, Director of Research, INSERM

HALF-DAY PRE-CONFERENCE WORKSHOPTuesday 26h September 2017

12.30 – 16.00Copthorne Tara Hotel, London, UK

Overview of Workshop:With the increasing use of various immunotherapy strategies in the clinic it is essential for immunomonitoring techniques to be conducted in order to follow the response of patients to therapy. Such investigations will enable the discovery of neoantigens that may contribute to the effi cacy of treatment. The potential cellular players, the use of screening techniques to monitor effects of treatment and an account of an immunotherapy trial will illustrate what is possible in clinical practice.

Reasons to attend:This half day workshop is aimed at both clinical and research investigators to give insights into how to develop tools for both developing new therapeutic strategies and how to monitor responses to treatment. This will enable you to design clinical trials and to set up laboratory investigations to evaluate response to immunotherapy.

Programme:

12.30 Registration & Coffee

13.00 Introduction

13.10 Innate lymphoid cells and immune intervention in cancer

Antoine Toubert, Head, Alloimmunity, Autoimmunity, Transplantation, INSERM

13.45 Resident memory T cell as surrogate markers of the effi cacy of cancer vaccines

Eric Tartour, Head, Laboratory of Clinical Immunology, Hopital Europeen George Pompidou

14.10 Discussion

14.30 Afternoon Tea

15.00 Using Cytome (mass cytometry) for immune-monitoring; challenges of big data management

Sharam Kordasti, Senior Lecturer,Kings College London

15.30 Wilms’ tumor 1 (WT1) RNA-electroporated dendritic cell vaccination as post-remission treatment to prevent or delay relapse in acute myeloid leukemia: fi nal results of a Phase II Study in 30 patients Zwi Berneman, Professor of Haematology, University of Antwerp

16.00 Workshop leader’s comments and close of the workshop

About the Workshop Leader:Dr. Rose Ann Padua (Ph.D) is an INSERM Director of Research (Unit 1131), previously Reader at the University of Wales College of Medicine and Deputy Director of the Leukemia Research Fund Preleukaemia Unit. As a Fulbright scholar, spent 18 months in the laboratories of the Nobel Laureate Michael Bishop at the University of California San Francisco; was a Consultant Clinical Scientist with the NHS at King’s College Hospital in London where as the Head of the Minimal Residual Disease Section she set up their molecular diagnostics program for adult leukaemia; is a molecular biology consultant for the International Atomic Energy Agency where she is transferring molecular assays to the developing countries for childhood leukaemia and adult lymphoma. Previously Chair of Working Group on novel therapies of European COST action and animal models Work Package for the European Leukaemia Network. Her research focus has been on developing animal models to understand the biology of myeloid malignancy and to use these as preclinical tools to evaluate targeted therapeutic options. The most innovative of the approaches under development is a DNA based immunotherapy strategy.

About INSERMInstitut National Santé et Recherche Medicale (INSERM) is the French National Institute of Health. Created in 1964, it employs 15,000 research investigators in 300 Research Units in France. INSERM forms partnerships with Universities and Hospitals. The Workshop leader is in such a mixed unit, Unité Mixte de Recherche-S1131), housed in the Institut Universitaire d’Hématologie (IUH), part of the Université Paris-Diderot in the Hôpital St-Louis campus and is focused on haematological malignancies.

SMi Pharmaceutical Forward Planner

SEPTEMBER

Cancer Vaccines27th - 28th

September 2017London, UK

Biosimilars and Biobetters27th - 28th

September 2017London, UK

OCTOBER

European Pharmaceutical Pricing & Reimbursement

11th - 12th October 2017

London, UK

Orphan Drugs and Rare Diseases18th - 19th

October 2017London, UK

NOVEMBER

Superbugs & Superdrugs USA13th - 14th

November 2017New Jersey, USA

Pharmaceutical

Microbiology East Coast13th - 14th

November 2017New Jersey, USA

Lyophilization USA

15th - 16th November 2017New Jersey, USA

Biosimilars North America

15th - 16th November 2017New Jersey, USA

Opthalmic Drug Development

28th - 29th November 2017

London, UK

DECEMBER

Cold Chain Distribution13th - 14th

December 2017London, UK

SPONSORSHIP AND EXHIBITION OPPORTUNITIESSMi offer sponsorship, exhibition, advertising and

branding packages, uniquely tailored to complement your company’s marketing strategy. Prime networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specifi c to your industry. Should you wish to

join the increasing number of companies benefi ting from sponsoring our conferences please call:

Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

Please complete fully and clearly in capital letters. Please photocopy for additional delegates.

Title: Forename:

Surname:

Job Title:

Department/Division:

Company/Organisation:

Email:

Company VAT Number:

Address:

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Mobile:

Switchboard:

Signature: Date:I agree to be bound by SMi’s Terms and Conditions of Booking.

ACCOUNTS DEPT

Title: Forename:

Surname:

Email:

Address (if different from above):

Town/City:

Post/Zip Code: Country:

Direct Tel: Direct Fax:

Payment: If payment is not made at the time of booking, then an invoice will be issued and must be paid immediately and prior to the start of the event. If payment has not been received then credit card details will be requested and payment taken before entry to the event. Bookings within 7 days of event require payment on booking. Access to the Document Portal will not be given until payment has been received.Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another delegate to take your place at any time prior to the start of the event. Two or more delegates may not ‘share’ a place at an event. Please make separate bookings for each delegate.Cancellation: If you wish to cancel your attendance at an event and you are unable to send a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge, providing that cancellation is made in writing and received at least 28 days prior to the start of the event. Regretfully cancellation after this time cannot be accepted. We will however provide the conferences documentation via the Document Portal to any delegate who has paid but is unable to attend for any reason. Due to the interactive nature of the Briefi ngs we are not normally able to provide documentation in these circumstances. We cannot accept cancellations of orders placed for Documentation or the Document Portal as these are reproduced specifi cally to order. If we have to cancel the event for any reason, then we will make a full refund immediately, but disclaim any further liability.Alterations: It may become necessary for us to make alterations to the content, speakers, timing, venue or date of the event compared to the advertised programme.Data Protection: The SMi Group gathers personal data in accordance with the UK Data Protection Act 1998 and we may use this to contact you by telephone, fax, post or email to tell you about other products and services. Unless you tick here □ we may also share your data with third parties offering complementary products or services. If you have any queries or want to update any of the data that we hold then please contact our Database Manager databasemanager@smi-online.co.uk or visit our website www.smi-online.co.uk/updates quoting the URN as detailed above your address on the attached letter.

Payment must be made to SMi Group Ltd, and received before the event, by one of the following methods quoting reference P-221 and the delegate’s name. Bookings made within 7 days of the event require payment on booking, methods of payment:

□ UK BACS Sort Code 300009, Account 00936418□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU Swift (BIC): LOYDGB21013, Account 00936418 IBAN GB48 LOYD 3000 0900 9364 18□ Cheque We can only accept Sterling cheques drawn on a UK bank.□ Credit Card □ Visa □ MasterCard □ American Express All credit card payments will be subject to standard credit card charges.

Card No: □□□□ □□□□ □□□□ □□□□Valid From □□/□□ Expiry Date □□/□□CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card

Cardholder’s Name:

Signature: Date:

I agree to be bound by SMi’s Terms and Conditions of Booking.

Card Billing Address (If different from above):

VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged on Document portal and literature distribution for all UK customers and for those EU Customers not supplying a registration number for their own country here. ______________________________________________________________________________________

If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email events@smi-online.co.uk

□ Please contact me to book my hotelAlternatively call us on +44 (0) 870 9090 711, email: events@smi-online.co.uk or fax +44 (0) 870 9090 712

I cannot attend but would like to purchase access to the following Document Portal/paper copy documentation Price Total□ Access to the conference documentation

on the Document Portal £499.00 + VAT £598.80□ The Conference Presentations – paper copy £499.00 - £499.00

(or only £300 if ordered with the Document Portal)

Unique Reference Number

Our Reference LVP-221

CANCER VACCINESConference: Wednesday 27th & Thursday 28th September 2017, Copthorne Tara Hotel, London, UK

Workshop: Tuesday 26th September 2017, Copthorne Tara Hotel, London, UK

4 WAYS TO REGISTERwww.cancervaccinesevent.com

FAX your booking form to +44 (0) 870 9090 712PHONE on +44 (0) 870 9090 711

POST your booking form to: Events Team, SMi Group Ltd, Ground & First Floor, 1 Westminster Bridge Road London, SE1 7XW, UK

DELEGATE DETAILS

Terms and Conditions of Booking

PAYMENT

VAT

DOCUMENTATION

VENUE Copthorne Tara Hotel, Scarsdale Place, Kensington, London W8 5SY

I would like to attend: (Please tick as appropriate) Fee Total

□ Conference & Workshop £2098.00 + VAT £2517.60□ Conference only £1499.00 + VAT £1798.80□ Workshop only £599.00 + VAT £718.80

PROMOTIONAL LITERATURE DISTRIBUTION □ Distribution of your company’s promotional

literature to all conference attendees £999.00 + VAT £1198.80

The conference fee includes refreshments, lunch, conference papers, and access to the Document Portal. Presentations that are available for download will be subject to distribution rights by speakers. Please note that some presentations may not be available for download. Access information for the document portal will be sent to the e-mail address provided during registration. Details are sent within 24 hours post conference.

CONFERENCE PRICES